Expression and clinical significance of collagenase-3 (MMP-13) in gastric cancer;Expresión y significación clínica de la MMP-13 (colagenasa-3) en el cáncer gástrico

Gastroenterologia y Hepatologia

Volumn 26, Issue 1, 2003, Pages 1-7

  Del Casar Lizcano, J M ^a   Vizoso Pineiro F ^a   Gonzalez Sanchez L O ^a   Martin Suarez A ^a   Gava, R ^a   Cuesta Fernandez E ^a   Diez Santisteban M C ^a  

^a HOSPITAL DE JOVE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; ENZYME ACTIVITY; ENZYME DEGRADATION; EXTRACELLULAR MATRIX; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CANCER;

EID: 0037259868     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13042205     Document Type: Article

References (54)

1. Vizoso FJ, Martínez A, Vázquez J, Lamelas ML, Rodil A, García-Muñiz JL. Significación biológica y clínica de las enzimas proteolíticas y sus inhibidores en los carcinomas humanos. Cir Esp 2000;68:471-85.
2. Werb Z, Alexander C, Adler R. Expression and function of matrix metalloproteinases in development. Marix 1992 (Suppl 1): 337-43.
3. Jeziorska M, Nagase H, Salamonsen LA, Woolley DE. Immunolocalization of the matrix metalloproteinases gelatinase B and stromalysin 1 in human endometrium throught the menstrual cycle. J Reproduction Fertility 1996; 107:43-51.
4. Fini M, Girard M, Matsubara M. Collagenolytic/gelatinolytic enzymes in corneal wound healing. Acta Ophthalmol 1992; 70:26-33.
5. Shima I, Sasaguri Y, Kusukawa J, Yamana H, Fujita H, Kakegawa T, et al. Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behabiour of esophageal carcinoma. Cancer 1992;70:2747-53.
6. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodelling. Trends Gen 1990;6:121-5.
7. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev Cancer 2002;2:161-74.
8. Ouchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y. Membrane type I matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 1997;272:2446-51.
9. Freije JM, Díez-Itza I, Balbín M, Sánchez LM, Blasco R, Tolivia J, et al. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 1994;269:16766-73.
10. Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Investig 1996;97:761-8.
11. Lindy O, Konttinen YT, Sorsa T, Ding Y, Santavirta S, Ceponis A, et al. Matrix metalloproteinase 13 (collagenase-3) in human rheumatoid synovium. Arthritis Rheum 1997;40:1391-9.
12. Knäuper V, Cowell S, Smith B, Lópex-Otín C, O'Shea M, Morris H, et al. The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3. J Biol Chem 1997;40:7608-16.
13. Ashworth JL, Murphy G, Rock MJ, Sherratt MJ, Shapiro SD, Shuttleworth CA, et al. Fibrillin degradation by matrix metalloproteinases: implications for connective tissue remodelling. Biochem J 1999;340:171-81.
14. Stahle-Bäckdahl M, Sandstedt B, Bruce K, Lindahl A, Jiménez MG, Vega JA, et al. Collagenase-3 (MMP- 13) is expressed during human fetal ossification and re-expressed in postnatal bone remodeling and rheumathoid arthritis. Lab Invest 1997;76: 717-28.
15. Balbín M, Fueyo A, López JM, Díez-Itza I, Velasco G, López-Otín C. Expression of collagenase-3 in the rat ovary during the ovulatory process. J Endocrinol 1996; 149:405-15.
16. Rudolph-Owen LA, Hulboy DL, Wilson CL, Mudhett J, Matrisian LM. Coordinate expression of matrix metalloproteinase family members in the uterus of normal, matrilysin-deficient, and stromelysin-1-deficient mice. Endocrinology 1997;138:4902-11.
17. Uría JA, Balbín M, López JM, Álvarez J, Vizoso F, Takigawa M, et al. Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor. Am J Pathol 1998;153:91-101.
18. Johansson N, Airola K, Grenman R, Kariniemi AL, Saarialho-Kere U, Kahari VM. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol 1997;151:499-508.
19. Cazorla M, Hernández L, Nadal A, Balbín M, López JM, Vizoso F, et al. Collagenase-3 expression is asociated with advanced local invasion in human squamous cell carcinomas of the larynx. J Pathol 1998; 186:144-50.
20. Airola K, Johansson N, Kariniemi AL, Kahari VM, Saarialho-Kere UK. Human collagenase-3 is expressed in malignant squamous epithelium of the skin. J lnvestig Dermatol 1997;109: 225-31.
21. Airola K, Karonen T, Vaalamo M, Lohi J, Kariniemi AL, Keski-Oja J, et al. Expression of collagenases-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer 1999;80:733-43.
22. Johansson N, Vaalamo M, Grenman S, Hietanen S, Klemi P, Saarialho-Kere U, et al. Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas. Am J Pathol 1999;154:469-80.
23. Bostrom PJ, Ravanti L, Reunanen N, Aaltonen V, Soderstrom KO, Kahari VM, et al. Expression of collagenase-3 (matrix metalloproteinase-13) in transitional cell carcinoma of the urinary bladder. Int J Cancer 2000;88:417-23.
24. Etoh T, Inoue H, Yoshikawa Y, Barnard GF, Kitano S, Mori M. Increased expression of collagenase-3 (MMP-13) and MTI-MMP in oesophageal cancer is related to cancer aggressiveness. Gut 2000;47:50-6.
25. Vaalamo M, Karjalainen-Lindsberg ML, Puolakkainen P, Kere J, Saarialho-Kere U. Distinct expression profiles of stromalysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinase-3 (TIMP-3) in intestinal ulcerations. Am J Pathol 1998;152:1005-14.
26. Uitto VJ, Airola K, Vaalamo M, Johansson N, Putnins EE, Firth JD, et al. Collagenase-3 (matrix metalloproteinase-13) expression is induced in oral mucosal epithelium during chronic inflammation. Am J Pathol 1998;152:1489-99.
27. Pérez-Ranios J, de Lourdes S, Vanda B, Selman M, Pardo A. Matrix metalloproteinases 2, 9, and 13, and tissue inhibitors of metalloproteinases 1 and 2 in experimental lung silicosis. Am J Respir Crit Care Med 1999;160:1274-82.
28. Sukhova GK, Schonbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999;99:2503-9.
29. Mao D, Lee JK, Van Vickle SJ, Thompson RW. Expression of collagenase-3 (MMP-13) in human abdominal aortic aneurysms and vascular smouth muscle cells in culture. Biochem Biophys Res Commun 1999;261:904-10.
30. Lund LR, Romer J, Bugge TH, Nielsen BS, Frandsen TL, Degen JL, et al. Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J 1999; 18:4645-56.
31. Nielsen BS, Rank F, López JM, Balbín M, Vizoso F, Lund LR, et al. Collagenase-3 expression in breast myofibroblasts as a marker of transition of ductal carcinoma in situ lesions to invasive ductal. Cancer Res 2001;61:7091-100.
32. Hermanek P, Sobin LH, editors. UICC TNM classification of malignant tumors (4th ed.). Berlin: Springer, 1992.
33. Lauren P. The two histological main types of gastric carcinoma: diffuse and so called intestinal type carcinomas: an attemp at a histological classification. Acta Pathol Microbiol Scand 1965; 64:31-49.
34. Vaitukaitis JL. Production of antisera with small doses of immunogen multiple intradermal injections. Methods Enzymol 1981;73:46-52.
35. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
36. Mantel N, Myers M. Problems of convergence of maximum likehood iterative procedures in multiparameter situations. J Am Statis Assoc 1971;66:484-91.
37. Cox DR. Regression models and life tables. J R Statist Soc B 1972;34:187-220.
38. Dixon WJ, editor. BMDP statistical software. Release 1990. Berkeley: University of California Press, 1986.
39. Grigioni WF, D'Errico A, Fortunato C, Florentino M, Mancini AM, Stetler-Stevenson WG, et al. Prognosis of gastric carcinoma revealed by interactions between tumors cells and basement membrane. Mod Pathol 1994;7:220-5.
40. Nuovo GJ, McConell PB, Simsir A, Valea F, French DL. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res 1995;55:267-75.
41. Sier CMF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996;74:413-7.
42. Allgayer H, Babic R, Beyer BCM, Grützner KU, Tarabichi A, Schildberg FW. Prognostic relevance of MMP-2 (72-kD collagenase IV) in gastric cancer. Oncol 1998;55:152-60.
43. Honda M, Mori M, Ueo H, Sugimachi K, Akiyoshi T. Matrix metalloproteinase-7 expression in gastric carcinoma. GUT 1996;39:444-8.
44. Senota A, Itoh F, Yamamoto H, Adachi Y, Hinoda Y, Imai K. Relation of matrilysin messenger RNA expression with invasive activity in human gastric cancer. Clin Exp Metastasis 1998;16:313-21.
45. Nomura H, Sato H, Seiki M, Mai M, Okada Y. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 1995;55:3263-6.
46. Knäuper V, Will H, López-Otín C, Smith B, Atkinson SJ, Stanton H, et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation: Evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme. J Biol Chem 1996;271:17124-31.
47. Cowell S, Knäuper V, Stewart ML, D'Ortho MP, Stanton H, Hembry RM, et al. Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase. Biochem J 1998;331:453-8.
48. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-70.
49. Uría JA, Stahle-Bäckdahl M, Seiki M, Fueyo A, López-Otín C. Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions. Cancer Res 1997;57:4882-8.
50. Gómez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997;74:111-22.
51. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FK. A synthetic metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1994;54:2087-91.
52. Drummond AH, Beckett P, Bone EA, Brown PD, Davis M, Galloway WA, et al. BB-2516: an orally bioavailable matrix metalloproteinase inhibitor with efficacy in animal cancer models. Proc Am Assoc Cancer Res 1995;36:100.
53. Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for long-term studies. Clin Cancer Res 1998;4:1101-11.
54. Tierney GM, Griffin NR, Stuart RC, Kasem H, Lynch KP, Lury JT, et al. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Eur J Cancer 1999;35:563-8.